MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Search

Smith & Nephew PLC ADR

Gesloten

32.92 3.42

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.89

Max

33.09

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

30.342

90.831

Dividendrendement

2.26

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+6.15% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.26%

2.20%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

15B

Vorige openingsprijs

29.5

Vorige sluitingsprijs

32.92

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jan 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 jan 2026, 00:00 UTC

Winsten

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 jan 2026, 23:47 UTC

Marktinformatie

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 jan 2026, 23:44 UTC

Marktinformatie

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 jan 2026, 23:39 UTC

Marktinformatie

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 jan 2026, 23:32 UTC

Marktinformatie

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 jan 2026, 22:56 UTC

Acquisities, Fusies, Overnames

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 jan 2026, 22:53 UTC

Acquisities, Fusies, Overnames

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 jan 2026, 22:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 jan 2026, 22:17 UTC

Marktinformatie

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 jan 2026, 22:09 UTC

Winsten

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 jan 2026, 22:08 UTC

Winsten

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 jan 2026, 21:53 UTC

Acquisities, Fusies, Overnames

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 jan 2026, 21:52 UTC

Acquisities, Fusies, Overnames

WuXi XDC Announces Positive Profit Alert for 2025

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Citigroup Acting as Financial Advisor to WuXi XDC

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 jan 2026, 21:51 UTC

Acquisities, Fusies, Overnames

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

14 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jan 2026, 21:49 UTC

Acquisities, Fusies, Overnames

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 jan 2026, 21:48 UTC

Acquisities, Fusies, Overnames

WuXi XDC Makes Cash Offer for BioDlink International

14 jan 2026, 21:13 UTC

Marktinformatie

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 jan 2026, 20:30 UTC

Marktinformatie
Winsten

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 jan 2026, 20:13 UTC

Marktinformatie

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 jan 2026, 20:08 UTC

Marktinformatie

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 jan 2026, 19:33 UTC

Marktinformatie

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 jan 2026, 19:06 UTC

Marktinformatie
Winsten

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

6.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.75 USD  6.15%

Hoogste 37.5 USD

Laagste 34 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat